Voltaren News and Research

RSS

Voltaren is a drug that is used to treat the symptoms of rheumatoid arthritis and is being studied in the prevention and treatment of some types of skin cancer. It blocks substances that cause inflammation and pain. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of cyclooxygenase inhibitor, a type of nonsteroidal anti-inflammatory drug (NSAID), and a type of antiangiogenesis agent. Also called diclofenac sodium.

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Impax Laboratories, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets.

9 Jun 2010

Endo Pharmaceuticals to acquire all outstanding shares of HealthTronics common stock

HealthTronics, Inc., a leading provider of urological products and services, today announced that it has signed a definitive merger agreement with Endo Pharmaceuticals pursuant to which Endo will acquire HealthTronics.

6 May 2010

Endo Pharmaceuticals signs agreement to acquire HealthTronics

Continuing to diversify, move into new growth areas beyond pharmaceuticals, and strengthen its commitment to improved patient outcomes in urology, Endo Pharmaceuticals today announced that it has signed an agreement to acquire HealthTronics, Inc., a leading U.S. provider of urological products and services.

6 May 2010

Endo Pharmaceuticals reports 9% increase in first-quarter 2010 revenues

Endo Pharmaceuticals today reported financial results for the first quarter 2010.

30 Apr 2010

Endo Pharmaceuticals' partners receive Paragraph IV Certification Notice regarding LIDODERM

Endo Pharmaceuticals announced today that its partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. have received a Paragraph IV Certification Notice from Watson Laboratories, Inc. advising of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of LIDODERM® (lidocaine topical patch 5%).

20 Jan 2010

Endo Pharmaceuticals receives FDA complete response letter for AVEED NDA

Endo Pharmaceuticals today announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its extended-duration testosterone undecanoate injection, AVEED(TM), for men diagnosed with low testosterone.

3 Dec 2009

Endo Pharmaceuticals reaches patent litigation settlement with LecTec

Endo Pharmaceuticals announced today that it has reached a settlement with LecTec Corporation on outstanding patent litigation related to LecTec's U.S. Patent Nos. 5,536,263 and 5,741,510.

11 Nov 2009

Third-quarter fiscal 2009 results announced by Endo Pharmaceuticals

Endo Pharmaceuticals today reported financial results for the third quarter of 2009.

29 Oct 2009

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

Endo Pharmaceuticals today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for FORTESTA(TM) (testosterone) 2% Gel for men diagnosed with low testosterone (Low T), also known as hypogonadism.

19 Oct 2009

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Endo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks.

3 Sep 2009

FDA extends review period for Endo Pharmaceuticals' testosterone undecanoate

Endo Pharmaceuticals announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the agency has extended its review period for its long-acting testosterone undecanoate injection for men diagnosed with hypogonadism, from Sept. 2, 2009 to Dec. 2, 2009.

3 Sep 2009

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

26 Aug 2009

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

Endo Pharmaceuticals announced today the commencement of a cash tender offer by its wholly-owned subsidiary, Endo Pharmaceuticals Solutions Inc., for any and all outstanding Ledgemont PhaRMA(SM) Secured 16% Notes due 2024 (the "Notes") of Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned subsidiary. The purpose of the tender offer is to acquire any and all Notes to reduce the consolidated interest expense of Endo.

26 Aug 2009

How to stop osteoarthritis pain

When arthritis affects the hands, a range of treatments may reduce pain and preserve joint mobility. The August issue of Mayo Clinic Health Letter provides an overview.

13 Aug 2009

Phosphagenics' diclofenac enters trial phase in humans

Phosphagenics Limited ("Phosphagenics") announced today that it has initiated a phase 1 human clinical trial using its patented drug delivery system, TPM, for the targeted delivery of a leading non steroidal anti-inflammatory drug (NSAID), diclofenac.

12 Nov 2008

Time for FDA to set the record straight on common painkillers

The U.S. Food and Drug Administration (FDA) has caused an unnecessary scare about some pain relievers by adding a warning to drugs that are safe, says Curt Furberg, M.D., Ph.D., from Wake Forest University School of Medicine.

25 Apr 2007

Latest studies reveal more risks with Vioxx

Two major studies by experts in the U.S. and Australia have provided new evidence of the cardiovascular and kidney risks attached to both COX-2 inhibitors and NSAID painkillers.

18 Sep 2006

Taking either COX-2 inhibitors or NSAIDs after a heart attack increases the risk of death

In recent years, evidence has shown that patients treated with selective cyclo-oxygenase-2 (COX-2) inhibitors are at increased risk of heart attack and death. COX-2 inhibitors are used primarily to treat pain and arthritis in patients at risk of gastrointestinal bleeding.

13 Nov 2005

Over-the-counter painkillers more likely to cause heart attacks than banned drug Vioxx

Researchers in the UK are saying that some of the most commonly used painkillers are more likely to cause heart attacks than Vioxx, the arthritis drug withdrawn from the market last year after it was linked to heart disease.

12 Jun 2005

Bextra withdrawn from market, strong warnings on popular painkillers

The U.S. Food and Drug Administration (FDA) has issued warnings that most popular painkillers can hurt the heart, stomach and skin, and they have told pharmaceutical giant Pfizer to withdraw Bextra a top selling painkiller.

10 Apr 2005